Artimplant Annual Accounts January - December, 2006.VASTRA FROLUNDA, Sweden -- Artimplant (STO:ARTIB): * Net revenue of 5.5 MSEK MSEK Meyer, Suozzi, English & Klein (New York law firm) MSEK Million Swedish Kroner (8.2)* * Net loss of 56.0 MSEK (36.2) * Net loss of 38.9 MSEK(36.2) if one time write-downs of capitalized R&D costs without cash effect are excluded * Earnings per share of -0.95 SEK SEK In currencies, this is the abbreviation for the Swedish Krona. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. (-0.73 SEK) * Strong sales increase for Artelon[R] CMC (Common Messaging Calls) A programming interface specified by the XAPIA as the standard messaging API for X.400 and other messaging systems. CMC is intended to provide a common API for applications that want to become mail enabled. 1. Spacer - about 1,050 (200) units sold to end customers during the fourth quarter * More than 3,000 patients have been treated with Artelon[R] devices through to 2006 * Received clearance to market Artelon[R] Tissue Reinforcement for reinforcement of rotator cuff tears in the USA * Four new Spacers received CE mark * Hans Rosen was employed as CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Events after the period * Promising results for Artelon[R] Tissue Reinforcement in foot applications were presented at the Swedish Foot Surgeon Society's yearly meeting * Artimplantos products received great attention during the worlds largest orthopedic conference AAOS AAOS American Academy of Orthopaedic Surgeons. AAOS American Academy of Orthopaedic Surgery (a) Numbers within brackets relate to the corresponding period last year Artimplant is a biomaterials company focused on solutions to problems in orthopedic and oral surgery. We restore health through the development, production, and marketing of degradable implants that regenerate body functions and improve quality of life. Our products, made from Artelon[R], meet unmet clinical needs and are marketed in a growing number of therapy areas. Artimplant produces implants for treatment of osteoarthritis in hands and feet, for shoulder injuries and other soft tissue injuries as well as dental applications. Forward-looking statements This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence ob·so·les·cent adj. 1. Being in the process of passing out of use or usefulness; becoming obsolete. 2. Biology Gradually disappearing; imperfectly or only slightly developed. ; general economic conditions; and other risks detailed from time to time in the Company's filings. This information was brought to you by Waymaker http://www.waymaker.net |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion